Skip to main content
    X

    Xeris Pharmaceuticals Inc (XERS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.70
    +0.04 (+0.24%)

    Market Cap: $3.04B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Xeris Pharmaceuticals Inc (XERS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Xeris Pharmaceuticals are Eton Pharmaceuticals (ETON), Amphastar (AMPH) and BioCryst Pharmaceuticals (BCRX). Xeris Pharmaceuticals trades at 139.2x earnings, against a median of 10.7x for the 11 of these companies with a P/E. By market cap, Xeris Pharmaceuticals ranks 5th of the 13 companies on this page; Kiniksa Pharmaceuticals (KNSA) is the largest at $7.57B.

    Peer Comparison

    XERS's ROIC of 15.5% is above the peer median of 7.1%, and its revenue growth of 44.2% is above the median of 11.6%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Xeris Pharmaceuticals (XERS)$3.04B139.2x8.2x-1.8%15.5%44.2%0.00%
    Eton Pharmaceuticals Inc (ETON)$1.84B36.7x13.0x35.3%37.0%157.9%0.00%
    Amphastar P (AMPH)$1.25B10.3x1.7x13.3%7.9%8.2%0.00%
    BioCryst Pharmaceuticals Inc (BCRX)$1.96B4.4x2.0x-37.4%24937.1%13.1%0.00%
    Indivior PLC Ordinary Shares (INDV)$4.28B6.6x2.4x32.8%109.0%13.4%0.00%
    Perrigo Company PLC (PRGO)$2.25B7.0x0.6x-43.3%-26.3%-5.2%7.17%
    Bausch Health Companies Inc (BHC)$3.13B1.7x0.3x-7.6%6.3%9.7%0.00%
    Supernus Pharmaceuticals, Inc. (SUPN)$1.52B12.7x2.0x32.8%N/A13.4%0.00%
    Pacira BioSciences, Inc. (PCRX)$1.46B20.0x2.0x5.1%4.2%-1.6%0.00%
    Prestige Brand Holdings Inc (PBH)$2.19B10.7x2.0x13.3%5.0%22.7%0.00%
    HUTCHMED DRC (HCM)$2.59BN/A4.7x3.3%-2.4%0.2%0.00%
    Kiniksa Pharmaceuticals Ltd (KNSA)$7.57B72.5x7.8x11.6%N/A58.1%0.00%
    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)$7.45B21.4x2.2x4.2%11.6%10.0%0.00%
    Peer median$2.22B10.7x2.0x8.3%7.1%11.6%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Xeris Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Drug Manufacturers - Specialty & Generic.

    CompanyAboutPeers
    Eton Pharmaceuticals Inc (ETON)
    Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases.
    ETON competitors
    Amphastar P (AMPH)
    Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation...
    AMPH competitors
    BioCryst Pharmaceuticals Inc (BCRX)
    BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small molecule drugs. The company is headquartered in Durham, North Carolina.
    BCRX competitors
    Indivior PLC Ordinary Shares (INDV)
    Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence...
    Perrigo Company PLC (PRGO)
    Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
    PRGO competitors
    Bausch Health Companies Inc (BHC)
    Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical...
    BHC competitors
    Supernus Pharmaceuticals, Inc. (SUPN)
    Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases...
    SUPN competitors
    Pacira BioSciences, Inc. (PCRX)
    Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United...
    PCRX competitors
    Prestige Brand Holdings Inc (PBH)
    Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States...
    PBH competitors
    HUTCHMED DRC (HCM)
    HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally.
    Kiniksa Pharmaceuticals Ltd (KNSA)
    Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical...
    KNSA competitors
    Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
    Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms...
    AMRX competitors

    Frequently Asked Questions About XERS

    Who are Xeris Pharmaceuticals' main competitors?

    The companies most similar to Xeris Pharmaceuticals include Eton Pharmaceuticals (ETON), Amphastar (AMPH), BioCryst Pharmaceuticals (BCRX), Indivior PLC Ordinary Shares (INDV) and Perrigo Company (PRGO), listed from the closest match.

    Who is Xeris Pharmaceuticals' biggest competitor?

    Kiniksa Pharmaceuticals (KNSA) is the largest of the similar companies at $7.57B; Eton Pharmaceuticals (ETON) is the closest match by business profile, size, sector and industry.

    How does XERS stock compare with its competitors?

    XERS' P/E is 139.2x against a peer median of 10.7x; its P/S is 8.2x against a peer median of 2.0x; its net margin is -1.8% against a peer median of 8.3%.

    Which of Xeris Pharmaceuticals' competitors pays a higher dividend?

    Xeris Pharmaceuticals pays no dividend. Perrigo Company (PRGO) has a higher forward dividend yield; Perrigo Company (PRGO) has the highest at 7.17%.

    Is Xeris Pharmaceuticals bigger than its competitors?

    No. Xeris Pharmaceuticals is 5th by market cap among the 13 companies on this page; the largest is Kiniksa Pharmaceuticals (KNSA) at $7.57B.